Top Markets
Coin of the day
RayzeBio, Inc. Common Stock RayzeBio, Inc. Common Stock

RayzeBio, Inc. Common Stock

RYZB
Rang in aandelen #5675
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs)... RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company's innovative pipeline also features RYZ801, a distinct peptide engineered to deliver Actinium-225 (Ac225) by targeting GPC3, intended for treating hepatocellular carcinoma (HCC). Additionally, RayzeBio is developing RYZ811, a companion diagnostic imaging agent comprising a peptide binder, a chelator, and Gallium-68 (Ga68). Another active development program involves a novel proprietary small molecule designed to target CA9, delivering Ac225 for potential use against clear cell renal cell carcinoma (ccRCC). The firm was established in 2020 and is headquartered in San Diego, California.
Aandeelprijs
$62.49
Laatst gesynchroniseerd: 2024-03-06
Marktkapitalisatie
$2.52B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel RayzeBio, Inc. Common Stock (RYZB)

Categorie

Dividendrendementgeschiedenis voor RayzeBio, Inc. Common Stock (RYZB)
Het dividendrendement (TTM) van RayzeBio, Inc. Common Stock (aandelsymbool: RYZB) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van RayzeBio, Inc. Common Stock (RYZB) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH